Humana Inc. (NYSE:HUM) had its target price hoisted by Morgan Stanley from $269.00 to $276.00 in a research report report published on Thursday morning. Morgan Stanley currently has an overweight rating on the insurance provider’s stock.

A number of other equities analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of Humana from a buy rating to a hold rating in a research note on Monday, April 24th. Citigroup Inc. initiated coverage on shares of Humana in a research note on Wednesday, June 28th. They set a buy rating and a $275.00 price objective on the stock. Evercore ISI reiterated an outperform rating and set a $240.00 price objective on shares of Humana in a research note on Tuesday, April 25th. BidaskClub upgraded shares of Humana from a hold rating to a buy rating in a research note on Wednesday, June 21st. Finally, Jefferies Group LLC reiterated a hold rating and set a $230.00 price objective (up from $221.00) on shares of Humana in a research note on Thursday, May 4th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the stock. The company has an average rating of Hold and an average price target of $244.35.

Humana (NYSE:HUM) opened at 247.28 on Thursday. The stock has a market capitalization of $35.74 billion, a price-to-earnings ratio of 20.34 and a beta of 0.91. Humana has a 12-month low of $163.50 and a 12-month high of $255.27. The stock’s 50 day moving average is $241.05 and its 200 day moving average is $224.57.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The firm had revenue of $13.53 billion for the quarter, compared to the consensus estimate of $13.61 billion. During the same period last year, the firm earned $2.30 earnings per share. Equities analysts predict that Humana will post $11.55 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/08/21/morgan-stanley-raises-humana-inc-hum-price-target-to-276-00.html.

The business also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Tuesday, August 29th will be issued a $0.40 dividend. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.65%. Humana’s dividend payout ratio is currently 13.06%.

In other Humana news, VP M Todoroff Christopher sold 22,935 shares of the firm’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $252.52, for a total value of $5,791,546.20. Following the completion of the transaction, the vice president now owns 24,001 shares of the company’s stock, valued at $6,060,732.52. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Bruce D. Broussard sold 12,000 shares of the firm’s stock in a transaction on Friday, August 11th. The stock was sold at an average price of $251.88, for a total transaction of $3,022,560.00. Following the completion of the transaction, the chief executive officer now directly owns 80,086 shares of the company’s stock, valued at approximately $20,172,061.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,406 shares of company stock valued at $10,355,086. Corporate insiders own 0.80% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC bought a new position in Humana during the first quarter worth about $6,021,000. ProShare Advisors LLC boosted its position in shares of Humana by 15.8% in the first quarter. ProShare Advisors LLC now owns 17,297 shares of the insurance provider’s stock valued at $3,566,000 after buying an additional 2,356 shares during the period. Profund Advisors LLC boosted its position in shares of Humana by 14.6% in the first quarter. Profund Advisors LLC now owns 6,131 shares of the insurance provider’s stock valued at $1,264,000 after buying an additional 782 shares during the period. Korea Investment CORP boosted its position in shares of Humana by 38.3% in the first quarter. Korea Investment CORP now owns 65,815 shares of the insurance provider’s stock valued at $13,567,000 after buying an additional 18,239 shares during the period. Finally, Mn Services Vermogensbeheer B.V. boosted its position in shares of Humana by 4.1% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 3,976 shares of the insurance provider’s stock valued at $766,000 after buying an additional 158 shares during the period. 99.13% of the stock is owned by institutional investors and hedge funds.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Stock Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related stocks with our FREE daily email newsletter.